S-MTC dihydrochloride  (Synonyms: S-Methyl-L-thiocitrulline dihydrochloride)

S-MTC (S-Methyl-L-thiocitrulline) dihydrochloride is a selective type I nitric oxide synthase (NOS) inhibitor.

NOS^[1]

S-MTC dihydrochloride (10 or 100 μM) reduces cellular NO release in the absence of Aβ_1-42. At 100 μM, S-MTC dihydrochloride decreases cell viability. S-MTC dihydrochloride (100 μM) significantly lowers nitrite production (11.2±1.1 μM) when compared to control (no NOS inhibitor exposure; 19.6±1.2 μM). Nitrite productions after Aβ_1-42 and L-NOARG (100 μM) or Aβ_1-42 and S-MTC dihydrochloride (100 μM) treatments are significantly lower than Aβ_1-42 alone (33.5±2.0 and 34.5±1.6 μM, respectively). S-MTC dihydrochloride (100 μM) is able to significantly reduce nitrite production (25.2±1.1 μM) as compared to Aβ_1-42 treatment alone (38.3±2.7 μM), when administered after Aβ_1-42 at the 1 h time point. S-MTC dihydrochloride (100 μM) concentration decreases both MTT (87±1% of control) and NR (80±1% of control, respectively) levels. The co-administration of S-MTC dihydrochloride (100 μM) and Aβ_1-42 significantly reverses the effects of Aβ_1-42 alone (72±2% vs 61±2% of control)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

S-MTC dihydrochloride (S-methyl-L-thiocitrulline) is a selective neuronal NOS-inhibitor. Following pretreatment with S-MTC dihydrochloride (i.c.v.), the HBO₂-induced antinociception is significantly antagonized. In Experiment #2, different groups of mice are pretreated with naltrexone hydrochloride (NTX) (3.0 mg/kg, i.p.), L-NAME (1.0 μg/mouse, i.c.v.), S-MTC dihydrochloride (1.0 μg/mouse, i.c.v.) or N⁵-(1-iminoethyl)-L-ornithine (L-NIO) (3.0 mg/kg, s.c.) 15-30 min prior to HBO₂ treatment. The antinociceptive effect assessed 90 min after HBO₂ treatment is completely abolished by NTX and L-NAME, antagonized by two-thirds by S-MTC dihydrochloride and largely unaffected by L-NIO (F=25.57, p<0.0001)^[2]. At a dose of 0.3 mg/kg, S-MTC dihydrochloride (SMTC) causes a rise in mean blood pressure (BP). At doses of 1.0, 3.0 and 10 mg/kg, S-MTC dihydrochloride causes falls in heart rate, rises in BP and vasoconstriction in all three vascular beds^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

278.20

C₇H₁₇Cl₂N₃O₂S

209589-59-3

Solid

White to off-white

N[C@@H](CCCNC(SC)=N)C(O)=O.[H]Cl.[H]Cl

Room temperature in continental US; may vary elsewhere.

-20°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

• [1]. Law A, et al. Neuroprotective and neurorescuing effects of isoform-specific nitric oxide synthase inhibitors, nitric oxide scavenger, and antioxidant against beta-amyloid toxicity. Br J Pharmacol. 2001 Aug;133(7):1114-24.  [Content Brief]

  [2]. Zelinski LM, et al. A prolonged nitric oxide-dependent, opioid-mediated antinociceptive effect of hyperbaric oxygenin mice. J Pain. 2009 Feb;10(2):167-72.  [Content Brief]

  [3]. Wakefield ID, et al. Comparative regional haemodynamic effects of the nitric oxide synthase inhibitors, S-methyl-L-thiocitrulline and L-NAME, in conscious rats. Br J Pharmacol. 2003 Jul;139(6):1235-43.  [Content Brief]